The Business Research Company The Business Research Company's At-Home Genetic Testing Market Analysis 2025 – Insights For Long-Term Investm ...

Spartanburg Regional Healthcare System (SRHS) in the US has chosen AccessDx Laboratory as its partner for a pharmacogenomics ...

"A diagnostic biomarker for IBD would be very impressive, but it would be even more impressive if we had a good biomarker ...

The Moratorium on Genetic Testing and Insurance, developed by the Ministry of Health and the Life Insurance Association, ...

Chicago-based AI-genomics leader introduces its pioneering GeneCancer™ and GenePGx™ tests to the European market, starting ...

The European direct-to-consumer genetic testing market is expected to reach USD 3.78 billion by 2035, growing from an estimated USD ...

Around 4,000 NHSGGC patients will take part in the two-year trial to see how genetic profiles affect responses to 60 common ...

The landmark trial will recruit up to 4,000 patients over the next two years in the NHS Greater Glasgow and Clyde area, to investigate how an individual’s genetic profile affects their response to 60 ...

His study, "Medical Policy Determinations for Pharmacogenetic Tests Among US Health Plans," uncovered significant differences in coverage decisions for pharmacogenetic tests across major US health ...

Pharmacogenetic testing for key metabolic genes, including DPYD, UGT1A1, and G6PD, can guide personalized treatment approaches. Methods: We analyzed samples from 3,519 individuals for genotyping using ...

Agilus’ comprehensive pharmacogenomics panel based on whole exome sequencing covers 59 PGx genes and 194 drugs. It also covers 32 genes associated with clinical annotations & dosing guidelines.